Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: AstraZeneca Makes Case For Vaxzevria Booster Against Omicron

As CEPI And SK Bio Look At 'Variant-Proof' Vaccines

Executive Summary

Also, AstraZeneca presents more promising data for its COVID-19 antibody cocktail Evusheld and Novavax says its vaccine is able to neutralize the Omicron variant. 

You may also be interested in...



Coronavirus Update: India Approves Multiple New Vaccines

India has issued emergency approvals for a number of new vaccines and extended eligible age groups for others, while developers of potential drug therapies in China see both gains and setbacks. 

Coronavirus Notebook: Vaccine Approvals In India Amid Wins And Losses For Drug Developers In China

India has issued emergency approvals for a number of new COVID-19 vaccines and extended eligible age groups for others, while developers of potential drug therapies in China have seen both gains and setbacks. 

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add seven new products, including Janssen-Cilag’s Rybrevant for treating patients with advanced non-small cell lung cancer.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel